News | November 06, 2023
Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The company is focussed on increasing the capacity utilizations while controlling costs
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
EPS for the period at Rs. (7.57)
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Subscribe To Our Newsletter & Stay Updated
